Literature DB >> 17511655

The proteins BACE1 and BACE2 and beta-secretase activity in normal and Alzheimer's disease brain.

J H Stockley1, C O'Neill.   

Abstract

The insidious progression of AD (Alzheimer's disease) is believed to be linked closely to the production, accumulation and aggregation of the approximately 4.5 kDa protein fragment called Abeta (amyloid beta-peptide). Abeta is produced by sequential cleavage of the amyloid precursor protein by two enzymes referred to as beta- and gamma-secretase. beta-Secretase is of central importance, as it catalyses the rate-limiting step in the production of Abeta and was identified 7 years ago as BACE1 (beta-site APP-cleaving enzyme 1). Soon afterwards, its homologue BACE2 was discovered, and both proteins represent a new subclass of the aspartyl protease family. Studies examining the regulation and function of beta-secretase in the normal and AD brain are central to the understanding of excessive production of Abeta in AD, and in targeting and normalizing this beta-secretase process if it has gone awry in the disease. Several reports indicate this, showing increased beta-secretase activity in AD, with recent findings by our group showing changes in beta-secretase enzyme kinetics in AD brain caused by an increased V(max). This article gives a brief review of studies which have examined BACE1 protein levels and beta-secretase activity in control and AD brain, considering further the expression of BACE2 in the human brain.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17511655     DOI: 10.1042/BST0350574

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  21 in total

1.  Amyloid precursor protein (APP) processing genes and cerebrospinal fluid APP cleavage product levels in Alzheimer's disease.

Authors:  L M Bekris; N M Galloway; S Millard; D Lockhart; G Li; D R Galasko; M R Farlow; C M Clark; J F Quinn; J A Kaye; G D Schellenberg; J B Leverenz; P Seubert; D W Tsuang; E R Peskind; C E Yu
Journal:  Neurobiol Aging       Date:  2010-12-31       Impact factor: 4.673

2.  A noncompetitive BACE1 inhibitor TAK-070 ameliorates Abeta pathology and behavioral deficits in a mouse model of Alzheimer's disease.

Authors:  Hiroaki Fukumoto; Hideki Takahashi; Naoki Tarui; Junji Matsui; Taisuke Tomita; Mitsuhiro Hirode; Masumi Sagayama; Ryouta Maeda; Makiko Kawamoto; Kazuko Hirai; Jun Terauchi; Yasufumi Sakura; Mitsuru Kakihana; Kaneyoshi Kato; Takeshi Iwatsubo; Masaomi Miyamoto
Journal:  J Neurosci       Date:  2010-08-18       Impact factor: 6.167

Review 3.  Transgenic mouse models of Alzheimer disease: developing a better model as a tool for therapeutic interventions.

Authors:  Masashi Kitazawa; Rodrigo Medeiros; Frank M Laferla
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

4.  Association of cerebrospinal fluid Aβ42 with A2M gene in cognitively normal subjects.

Authors:  Steven P Millard; Franziska Lutz; Ge Li; Douglas R Galasko; Martin R Farlow; Joseph F Quinn; Jeffrey A Kaye; James B Leverenz; Debby Tsuang; Chang-En Yu; Elaine R Peskind; Lynn M Bekris
Journal:  Neurobiol Aging       Date:  2013-09-04       Impact factor: 4.673

Review 5.  Study of Exosomes Shed New Light on Physiology of Amyloidogenesis.

Authors:  Guillaume van Niel
Journal:  Cell Mol Neurobiol       Date:  2016-03-17       Impact factor: 5.046

6.  Genetic pathway-based hierarchical clustering analysis of older adults with cognitive complaints and amnestic mild cognitive impairment using clinical and neuroimaging phenotypes.

Authors:  Chantel D Sloan; Li Shen; John D West; Heather A Wishart; Laura A Flashman; Laura A Rabin; Robert B Santulli; Stephen J Guerin; C Harker Rhodes; Gregory J Tsongalis; Thomas W McAllister; Tim A Ahles; Stephen L Lee; Jason H Moore; Andrew J Saykin
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2010-07       Impact factor: 3.568

7.  Population PKPD modeling of BACE1 inhibitor-induced reduction in Aβ levels in vivo and correlation to in vitro potency in primary cortical neurons from mouse and guinea pig.

Authors:  Juliette Janson; Susanna Eketjäll; Karin Tunblad; Fredrik Jeppsson; Stefan Von Berg; Camilla Niva; Ann-Cathrin Radesäter; Johanna Fälting; Sandra A G Visser
Journal:  Pharm Res       Date:  2013-10-03       Impact factor: 4.200

Review 8.  Omega-3 fatty acids: potential role in the management of early Alzheimer's disease.

Authors:  Gregory A Jicha; William R Markesbery
Journal:  Clin Interv Aging       Date:  2010-04-07       Impact factor: 4.458

9.  The expression of microRNA miR-107 decreases early in Alzheimer's disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1.

Authors:  Wang-Xia Wang; Bernard W Rajeev; Arnold J Stromberg; Na Ren; Guiliang Tang; Qingwei Huang; Isidore Rigoutsos; Peter T Nelson
Journal:  J Neurosci       Date:  2008-01-30       Impact factor: 6.167

10.  Upregulation of BACE1 and beta-amyloid protein mediated by chronic cerebral hypoperfusion contributes to cognitive impairment and pathogenesis of Alzheimer's disease.

Authors:  Cai Zhiyou; Yan Yong; Sun Shanquan; Zhang Jun; Huang Liangguo; Yan Ling; Li Jieying
Journal:  Neurochem Res       Date:  2009-01-04       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.